AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03238729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Failure Education and Management App
Description: Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
Study NCT03238729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Literature
Description: Patients will be provided standard literature about heart failure and the management of heart failure.
Study NCT01450943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECONDARY dressing gauze and tape
Description: SECONDARY dressing gauze and tape
Study NCT01450943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SECONDARY dressing gauze and tape
Description: SECONDARY dressing gauze and tape
Study NCT01450943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement, irrigation
Description: debridement, irrigation
Study NCT01324856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatico gastro anastomosis
Description: After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
Study NCT01324856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejuno anastomosis
Description: After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
Study NCT01450943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: debridement, irrigation
Description: debridement, irrigation
Study NCT01450943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermagraft
Description: Dermagraft per company protocol
Study NCT01450943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oasis
Description: Oasis per company protocol
Study NCT02689375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senza Spinal Cord Stimulation system
Description: Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
Study NCT02688972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold water immersion
Description: The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
Study NCT02688972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The volunteers stayed in rest about 10 minutes
Study NCT00647777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Tablets 5 mg
Description: 5mg, single dose fed
Study NCT00647777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa® Tablets 5 mg
Description: 5mg, single dose fed
Study NCT04472923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment
Description: Patients belonging to the control group received conventional physical therapy program in the form of:~1. Dietetic Regulation: The diet was given in the form of the bulk-forming diet, fruits, vegetables, cereals, and bran.~2. Pelvic floor muscle exercises (Kegal exercises): The patient was instructed to lie crock lying position with knees bent. He/she was instructed to pull his/her pelvic muscles upward and inward and hold the contraction for 6 seconds as if to hold back a defecation movement, followed by relaxation for 6 seconds. The exercise was repeated 25 times. Gradually increase the time until reaching 10 seconds of contraction and relaxation for each with repetition up to 30 times. The exercises applied twice per week for 3 months.
Study NCT02932917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MapMySmoke
Description: Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
Study NCT01705002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Epicatechin 0.5 mg/kg
Description: EC 0.5
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 0.5 mg/kg
Description: EC 0.5
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Epicatechin 1.0 mg/kg
Description: EC 1.0
Study NCT02292342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 1.0 mg/kg
Description: EC 1.0
Study NCT04162600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG
Description: Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
Study NCT04162600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Rabies Vaccine
Description: A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
Study NCT04162600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG
Description: Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp.
Study NCT01872897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Alginate Double Action Tablets
Description: Four tablets as a single dose
Study NCT01872897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets as a single dose
Study NCT00485433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl given during hernia repair
Study NCT00485433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: SKY0402 given during hernia repair
Study NCT04472923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months.
Study NCT05547763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates
Description: under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
Study NCT02371759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L+C maxillary anesthesia
Description: Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
Study NCT02371759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L+C mandibular anesthesia
Description: Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
Study NCT02371759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L+E maxillary anesthesia
Description: Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
Study NCT02371759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L+E mandibular anesthesia
Description: Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
Study NCT02746900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: McDonald cervical cerclage
Study NCT01345292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthwash
Description: Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
Study NCT01345292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate toothpaste
Description: Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
Study NCT01345292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium fluoride toothpaste
Description: Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
Study NCT02525705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Glucose
Description: 1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
Study NCT01879904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Description: This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
Study NCT02161510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2248
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
Study NCT02995343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypogastric and/or uterine artery ligation
Study NCT03695432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flubio
Description: Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
Study NCT03695432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacidofil
Description: Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
Study NCT03695432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
Study NCT03695432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotic
Description: Capsul
Study NCT01896037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Description: Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
Study NCT03556605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OneTouch Reveal® Mobile APP system
Description: Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
Study NCT03556605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Current Blood Glucose Monitor
Description: Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
Study NCT01705002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
Study NCT01705002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
Study NCT00030407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
Study NCT00030407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
Study NCT05685017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nur Aisiyah Widjaja
Description: Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
Study NCT02091349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: polydextrose
Description: polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
Study NCT02091349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polydextrose
Description: polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
Study NCT02091349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: soluble corn fiber
Description: nutirose- 7, 14, or 21 grams/day
Study NCT02091349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soluble corn fiber
Description: nutirose- 7, 14, or 21 grams/day
Study NCT03147833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sport beverages Protein
Description: Beverage ingested before each night sleep during the intervention
Study NCT03147833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sport beverages Carbohydrate
Description: Beverage ingested before each night sleep during the intervention
Study NCT00876356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated Linoleic Acid (CLA)
Description: CLA 4.5g/day in three divided doses p.o. for 12 weeks
Study NCT00876356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Olive oil 4.5g/day x 12 weeks
Study NCT02609516 — intervention group
Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on the retrospective analysis of linked electronic health records.
Study NCT02653729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behaviour therapy
Study NCT02653729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Espidone
Study NCT02653729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Espidone
Study NCT02653729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olepra
Study NCT02653729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olepra
Study NCT02653729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donu
Study NCT02653729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donu
Study NCT01074905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
Study NCT01074905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: 25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
Study NCT01074905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine/Primaquine
Description: Chloroquine 3 days and Primaquine 14 days
Study NCT03804008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided corticosteroid injection
Description: A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
Study NCT03804008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy-slow resistance training
Description: Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
Study NCT03804008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fundamental advice and a silicone heel cup
Description: Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
Study NCT02414659 — intervention group
Intervention type: PROCEDURE
Intervention: Umbilical cord blood collection, in-utero
Description: Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
Study NCT03911713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: VX-561 tablets for oral administration.
Study NCT03911713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: 150-mg film-coated tablet for oral administration.
Study NCT03911713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA.
Study NCT03911713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebos matched to VX-561.
Study NCT02641132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C 0.02%
Description: Pterygium excision with application of mitomycin C
Study NCT02641132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C 0.02%
Description: Pterygium excision with application of mitomycin C
Study NCT02641132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium surgery
Description: Two different procedures- excision of the head and the body and excision of the head only
Study NCT02641132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium surgery
Description: Two different procedures- excision of the head and the body and excision of the head only
Study NCT03265665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTION Intervention
Description: The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.